Psychedelics: New Frontiers in Alternative Medicine

View our interactive May/June 2022 digital edition.

What would legalization and widespread availability of psilocybin therapy look like? Here, we connect with Dr. Sunil Aggarwal, a palliative care physician and cofounder of the Advanced Integrative Medical Science Institute (AIMS) in Seattle, Washington, to find out.

In this interview, Donaghue Woodman, Head of Research and Development and Chief Medical Information Officer at Cannsun, provides an in-depth look at their current clinical trial on the effects of psilocybin in treating a prevalent yet unresolved issue in South Africa.

Here we present an outline of the areas that might be critical in creating an infrastructure for building the right psilocybin production space.

A brief summary of a new peer-reviewed paper detailing the assembly of a highly contiguous draft reference genome for the Psilocybe cubensis mushroom by Kevin McKernan, Medicinal Genomics Chief Science Officer, and colleagues.

An overview of the therapeutic role of psychedelics that goes back thousands of years, as well as the new research and the application of microdosing principles that have created renewed interest in the power of psychedelics.

Dr. Denise C. Vidot, an epidemiologist at the University of Miami and Founder of the International Cannabis & Psychedelic Research Collaborative, shares her research background, a small preview of her talk, “Co-Use of Cannabis and Psilocybin to Manage Mental Health Amid the COVID-19 Pandemic: Preliminary Results from the International COVID-19 Cannabis Health Study,” and more.